Skip to main content
SpringerLink
Log in

Letrozole is an effective option in the treatment of early-stage or advanced breast cancer in postmenopausal women

  • Drugs and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Beslija S, Bonneterre J, Burstein HJ, et al. Consensus on medical treatment of metastatic breast cancer. Breast Cancer Res Treat 2003; 81 Suppl. 1: S1–7

    Article  Google Scholar 

  2. Simon MS, Ibrahim D, Newman L, et al. Efficacy and economics of hormonal therapies for advanced breast cancer. Drugs Aging 2002; 19(6): 453–63

    Article  PubMed  CAS  Google Scholar 

  3. Come SE, Buzdar AU, Arteaga CL, et al. Second international conference on recent advances and future directions in endocrine manipulation of breast cancer: summary consensus statement. Clin Cancer Res 2003 Jan; 9 Suppl. : 443s–6s

    PubMed  Google Scholar 

  4. Simpson D, Curran MP, Perry CM. Letrozole: a review of its use in postmenopausal women with breast cancer. Drugs 2004; 64(11): 1213–30

    Article  PubMed  CAS  Google Scholar 

  5. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003 Nov 6; 349(19): 1793–802

    Article  PubMed  CAS  Google Scholar 

  6. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001 Nov; 12(11): 1527–32

    Article  PubMed  CAS  Google Scholar 

  7. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003 Jun 1; 21(11): 2101–9

    Article  PubMed  CAS  Google Scholar 

  8. Mouridsen H, Sun Y, Gershanovich M, et al. Significantly longer time to progression for Femara (letrozole) in patients with or without prior adjuvant tamoxifen: updated analysis of the double-blind, randomized, multinational phase III trial of letrozole compared to tamoxifen as first-line hormonal therapy for advanced breast cancer [abstract no. 256]. 25th Annual San Antonio Breast Cancer Symposium; 2002 Dec 11–14; San Antonio

  9. Smith IE. Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy. J Steroid Biochem Mol Biol 2003 Sep; 86(3-5): 289–93

    Article  PubMed  CAS  Google Scholar 

  10. Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001 M 15; 19(14): 3357–66

    PubMed  CAS  Google Scholar 

  11. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16: 453–61

    PubMed  CAS  Google Scholar 

  12. Rose C, Vtoraya O, Pluzanska A, et al. An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 2003 Nov; 39(16): 2318–27

    Article  PubMed  CAS  Google Scholar 

  13. Novartis Oncology. About Femara: European summary of product characteristics [online]. Available from URL: http://www.femara.com [Accessed 2004 Sep 2]

  14. Novartis Oncology. Femara prescribing information [online]. Available from URL: http://www.us.femara.com [Accessed 2004 Sep 2]

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Letrozole is an effective option in the treatment of early-stage or advanced breast cancer in postmenopausal women. Drugs Ther. Perspect 21, 1–4 (2005). https://doi.org/10.2165/00042310-200521010-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200521010-00001

Search

Navigation